Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, May 22, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Ami Fadia Reiterated (BIIB) at Strong Buy and Held Target at $294 on, May 22nd, 2024
Ami Fadia of Needham, Reiterated "Biogen Inc." (BIIB) at Strong Buy and Held Target at $294 on, May 22nd, 2024.
Ami has made no other calls on BIIB in the last 4 months.
There are 17 other peers that have a rating on BIIB. Out of the 17 peers that are also analyzing BIIB, 6 agree with Ami's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Laura Chico of "Wedbush" Maintained at Hold with Increased Target to $215 on, Thursday, April 25th, 2024
- Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $200 on, Thursday, April 25th, 2024
- Colin Bristow of "UBS" Maintained at Hold with Decreased Target to $214 on, Wednesday, April 17th, 2024
- Geoff Meacham of "B of A Securities" Maintained at Hold with Decreased Target to $260 on, Friday, April 12th, 2024
- Chris Schott of "JP Morgan" Maintained at Hold with Decreased Target to $240 on, Thursday, April 11th, 2024
- Mohit Bansal of "Wells Fargo" Downgraded from Buy to Hold and Decreased Target to $240 on, Wednesday, February 14th, 2024
These are the ratings of the 11 analyists that currently disagree with Ami
- Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy and Held Target at $340 on, Thursday, May 16th, 2024
- Morten Herholdt of "HSBC" Maintained at Strong Buy with Increased Target to $342 on, Friday, May 3rd, 2024
- Jay Olson of "Oppenheimer" Maintained at Buy and Held Target at $270 on, Monday, April 29th, 2024
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $300 on, Thursday, April 25th, 2024
- Brian Abrahams of "RBC Capital" Reiterated at Buy and Held Target at $364 on, Tuesday, March 5th, 2024
- Salim Syed of "Mizuho" Maintained at Strong Buy with Decreased Target to $277 on, Thursday, February 22nd, 2024
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $305 on, Tuesday, February 20th, 2024
- Eric Schmidt of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $311 on, Tuesday, February 20th, 2024
- Evan Seigerman of "BMO Capital" Maintained at Buy with Decreased Target to $285 on, Wednesday, February 14th, 2024
- Brian Skorney of "Baird" Maintained at Buy with Decreased Target to $316 on, Wednesday, February 14th, 2024
- Christopher Raymond of "Piper Sandler" Maintained at Buy with Decreased Target to $325 on, Wednesday, February 14th, 2024
